June 28, 2013
MiMedx Group, Inc. (NASDAQ: MDXG)
, an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that the Company's wound care allograft, EpiFix®, received reimbursement coverage by Medicare Contractor Wisconsin Physician Services (WPS), effective
July 1, 2013
Parker H. "Pete" Petit, Chairman and CEO, said, "We are pleased to receive approval from another of the Medicare Contractors. The approval by WPS brings the total Medicare Contractors agreeing to reimburse for our EpiFix® wound care tissue grafts to six of the nine. As we have stated previously, we have aggressively pursued this critical aspect of our reimbursement strategy, and we are very happy to see the results from that initiative continue to expand the geography in which EpiFix® is approved for coverage."
, President and COO, commented, "The documented efficacy and cost-effectiveness of EpiFix® is driving the rapid pace at which we are securing approvals from the Medicare Contractors. We expect that a number of our publications will have a significant influence on the reimbursement approval from the remaining Medicare Contractors. Most recent was the peer-reviewed publication of the compelling results from our randomized controlled clinical trial of patients with diabetic foot ulcers. In addition, the results of the crossover study from that clinical trial have been accepted for publication, and over the next few months, we expect several additional clinical studies to be published. These publications should further support the efficacy and cost-effectiveness of EpiFix®."
WPS has approved EpiFix® and has indicated its use for neuropathic diabetic foot ulcers and venous stasis ulcers that have failed to respond to conservative measures. Payment is approved for up to 5 applications per ulcer.